ArticleMolecular psychiatry2025
Functional defects in FOXG1 variants predict the severity of brain anomalies in FOXG1 syndrome.
Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Foxg1 regulates the development of microvillous cells in the olfactory epithelium.Developmental biology · 2026Article
- Article
- Novel advanced patient-derivedFrontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
FOXG1 (Forkhead Box G1) is a critical transcription factor for brain development, regulating progenitor cell proliferation, neuronal migration, and cortical circuit assembly. Pathogenic FOXG1 variants lead to FOXG1 syndrome, a neurodevelopmental disorder characterized by severe brain anomalies and cognitive impairments. Despite efforts to correlate genetic variants with clinical outcomes, the precise relationship remains elusive. Here, we analyzed clinical severity and brain anomalies in 14 individuals with FOXG1 variants, investigating how these variants impact FOXG1's properties and functions. We uncovered a strong correlation between the severity of brain anomalies in affected individuals and functional alterations of these variants. Variants with very low protein expression were associated with moderate-to-severe brain anomalies. A luciferase reporter assay was used to assess the ability of FOXG1 variants to repress COUP-TFI (NR2F1) expression-a function of FOXG1 validated through single-cell RNA-sequencing (scRNA-seq). Variants losing COUP-TFI repression ability by binding to COUP-TFI's enhancer region consistently caused moderate-to-severe brain anomalies. Furthermore, in utero electroporation (IUE) in embryonic mouse brains was employed to study their impact on neuronal migration and differentiation. Electroporation of wild-type Foxg1 delayed neuronal migration and altered their cell fate. Remarkably, variants associated with moderate-to-severe brain anomalies impaired these functions, while those with mild brain anomalies caused partial impairment. Thus, by combining protein expression, COUP-TFI repression, and neuronal migration assays, we developed a patient stratification paradigm for predicting the severity of FOXG1 syndrome. This workflow successfully differentiated 92.3% of cases, facilitating early diagnosis and guiding future therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.